Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $11.33 and last traded at $11.50, with a volume of 1605555 shares. The stock had previously closed at $12.40.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DYN. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective on the stock. Chardan Capital reissued a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, February 28th. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $48.85.

Dyne Therapeutics Price Performance

The company has a fifty day moving average price of $15.10 and a two-hundred day moving average price of $25.73. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -3.34 and a beta of 1.11.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently made changes to their positions in the company. US Bancorp DE increased its holdings in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after purchasing an additional 1,212 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in Dyne Therapeutics in the 3rd quarter valued at approximately $1,588,000. Victory Capital Management Inc. lifted its position in Dyne Therapeutics by 59.4% in the 3rd quarter. Victory Capital Management Inc. now owns 30,537 shares of the company's stock worth $1,097,000 after buying an additional 11,385 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Dyne Therapeutics by 4.3% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 40,091 shares of the company's stock valued at $1,440,000 after buying an additional 1,636 shares during the period. Finally, KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after acquiring an additional 751 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.